Succinylcholine: Adverse effects and alternatives in emergency medicine

https://doi.org/10.1016/S0735-6757(99)90168-7Get rights and content

Abstract

Succinylcholine has long been the favored neuromuscular blocking agent for emergent airway management because of its rapid onset, dependable effect, and short duration. However, it has a plethora of undesirable side effects, ranging from the inconsequential to the catastrophic. When patients requiring tracheal intubation present with potential contraindications to succinylcholine use, the emergency physician will need to substitute a rapid-onset nondepolarizing neuromuscular blocking agent, such as rocuronium or mivacurium. An understanding of the pharmacology of these agents is essential.

References (124)

  • DR Cook et al.

    Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure

    Br J Anaesth

    (1992)
  • JE Caldwell et al.

    Comparison of the neuromuscular block induced by mivacurium, suxamethonium and atracurium during nitrous oxide-fentanyl anaesthesia

    Br J Anaesth

    (1989)
  • WJ Book et al.

    Adverse effects of depolarising neuromuscular blocking agents

    Drug Safety

    (1994)
  • Dr Bevan et al.

    Succinylcholine

  • JJ Savarese et al.

    Pharmacology of muscle relaxants and their antagonists

  • DR Cook

    Pharmokinetics of SCC

    Clin Pharm Ther

    (1976)
  • TA Torda et al.

    Pharmacokinetics and pharmacodynamics of suxamethonium

    Anaesth Intensive Care

    (1997)
  • DR Cook et al.

    Pediatric anesthetic pharmacology

  • JE Szalados

    Effect of d-tubocurare pretreatment on succinylcholine twitch augmentation and neuromuscular blockade

    Anesth Analg

    (1990)
  • FK Puhringer et al.

    Evaluation of the endotracheal intubating conditions of rocuronium and succinylcholine in outpatient surgery

    Anesth Analg

    (1992)
  • JL Benumof et al.

    Critical hemoglobin desaturation will occur before return to an unparalyzed state after administration of 1 mg/kg of intravenous succinylcholine

    Anesthesiology

    (1997)
  • SM Yentis

    Suxamethonium and hyperkalemia

    Anaesth Intensive Care

    (1992)
  • J Norman

    Succinylcholine

    Curr Opin Anesth

    (1991)
  • RD Henning et al.

    Plasma potassium after halothane-suxamethonium induction in children

    Anaesthesia

    (1982)
  • WF List

    Serum potassium changes during induction of anaesthesia

    Br J Anaesth

    (1967)
  • W Evers et al.

    Changes in plasma potassium and calcium levels and in the electrocardiogram after a single dose of succinylcholine preceded by d-tubocurarine

    Can Anaesth Soc J

    (1976)
  • M-E Koller et al.

    Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats

    Acta Anaesthesiol Scand

    (1984)
  • JH Cook

    Effects of suxamethonium on introcular pressure

    Anaesthesiology

    (1981)
  • WY Abdulla et al.

    Intraocular pressure changes in response to endotracheal intubation facilitated by atracurium or succinylcholine with or without lidocaine

    Acta Anaesth Belg

    (1992)
  • RE Kelly et al.

    Succinylcholine increases intraocular pressure in the human eye with the extraocular muscles detached

    Anesthesiology

    (1993)
  • MM Libonati et al.

    Use of succinylcholine in open eye surgery

    Anesthesiology

    (1985)
  • RD Miller et al.

    Inhibition of succinylcholine-induced increase in intragastric pressure

    Anesthesiology

    (1971)
  • G Smith et al.

    Gastroesophageal pressure gradient changes produced by induction of anesthesia and suxamethonium

    Br J Anaesth

    (1978)
  • AA Artru

    Muscle relaxation with succinylcholine or vecuronium does not alter the rate of CSF production or resistance to reabsorption of CSF in dogs

    Anesthesiology

    (1988)
  • JE Cottrell et al.

    Intracranial and hemodynamic changes after succinylcholine in cats

    Anesth Analg

    (1983)
  • AM Lam et al.

    Succinylcholine and intracranial pressure: A cause for pause

    Anesth Analg

    (1984)
  • WL Lanier et al.

    Cerebral stimulation following succinylcholine in dogs

    Anesthesiology

    (1986)
  • WD Kovarick et al.

    Succinylcholine does not change intracranial pressure, cerebral blood flow velocity or the electroencephalogram in patients with neurologic injury

    Anesth Analg

    (1994)
  • MM Brown et al.

    The effect of suxamethonium on the intracranial pressure and the cerebral perfusion pressure in patients with severe head injury following blunt trauma

    Eur J Anaesth

    (1996)
  • AHF Galindo

    Succinylcholine and cardiac excitability

    Anesthesiology

    (1962)
  • V Nigrovic

    Succinylcholine cholinoceptors and catecholamines

    Can Anaesth Soc J

    (1984)
  • EP Sherman et al.

    Bradycardia following sufentanil-succinylcholine

    Anesthesiology

    (1987)
  • J Lerman

    The heart rate response to succinylcholine in children: A comparison of atropine and glycopyrrolate

    Can Anaesth Soc J

    (1984)
  • SJ Basta

    Modulation of histamine release by neuromuscular blocking drugs

    Curr Opin Anesth

    (1992)
  • RD Miller

    Advantages of giving d-tubocurare before succinylcholine

    Anesthesiology

    (1972)
  • JB Brodsky et al.

    Pancuronium pretreatment and post-succinylcholine myalgias

    Anesthesiology

    (1979)
  • EC Jansen et al.

    Objective measurement of succinylcholine-induced fasciculations and the effects of pretreatment with pancuronium or gallamine

    Anesthesiology

    (1979)
  • NL Pace

    Prevention of succinylcholine-induced myalgias

    Anesth Analg

    (1990)
  • C Lee

    Succinylcholine update

    Curr Opin Anesth

    (1993)
  • Cited by (54)

    • Neuromuscular blocking agents and skeletal muscle relaxants

      2022, Side Effects of Drugs Annual
      Citation Excerpt :

      These agents are categorized as either depolarizing or nondepolarizing neuromuscular blockers and use of these medications results in transient paralysis. Succinylcholine, the only available depolarizing agent, has been associated with hyperkalemia, bradycardia, malignant hyperthermia, muscle fasciculations, myalgias, rhabdomyolysis, and increased intraocular and intracranial pressure (Stollings et al., 2014 [R]; Orebaugh, 1999 [R]). The risk of adverse effects is increased in patients with plasma cholinesterase (butyrylcholinesterase) deficiency due its role in the metabolism of succinylcholine (Fig. 1) (Brazzolotto et al., 2021 [A]; Millet et al., 2021 [c]; Sasidharan & Dhillon, 2021 [A]).

    • Approach to Acute Weakness

      2021, Emergency Medicine Clinics of North America
      Citation Excerpt :

      If rapid sequence intubation is deemed necessary, consider avoiding depolarizing neuromuscular blocking agents such as succinylcholine. These agents carry the risk of potentially fatal hyperkalemia in those with neurologic disease by amplifying the succinylcholine-related cellular potassium release.4,5 For most relevant conditions, this response occurs in those with symptoms or illness for 3 or more days.

    • A comparison between succinylcholine and rocuronium on the recovery profile of the laryngeal muscles during intraoperative neuromonitoring of the recurrent laryngeal nerve: A prospective porcine model

      2013, Kaohsiung Journal of Medical Sciences
      Citation Excerpt :

      The second benefit is pharmacological safety. However, diverse adverse effects ranging from minor (e.g., muscle pain, dysrhythmia) to lethal (e.g., malignant hyperthermia, hyperkalemia) limit its clinical application [13,14]. Succinylcholine also has a short duration; however, it is responsible for most incidents of NMBA-related anaphylaxis [15].

    View all citing articles on Scopus
    View full text